1. Introduction {#s0005}
===============

Glucose transporter type I deficiency syndrome (GLUT1DS) is a treatable encephalopathy, caused by a defect of glucose uptake, mediated by GLUT1, at the blood brain barrier and into brain cells due to mutations in *SLC2A1* gene (solute carrier family 2 member 1) ([@bb0185]). The classical phenotype includes a range of complex movement disorders, drug-resistance epilepsy, mental retardation, and acquired microcephaly ([@bb0065], [@bb1200]). Less severe disorders mainly characterized by paroxysmal exercised-induced dyskinesia (PED) and 'generalized epilepsies', either alone or in combination, have been reported ([@bb0015], [@bb0155], [@bb0160], [@bb0165]). When epilepsy is the main symptom, absence seizures (AS), mainly with early onset, seem to be the most frequent clinical expression of *SLC2A1* mutations and in individual cases AS may be phenotypically indistinguishable from absences of the genetic generalized epilepsies (GGE; formerly known as idiopathic generalized epilepsies) ([@bb0015], [@bb9000], [@bb0155]). Furthermore, during childhood, the most common EEG abnormalities are 2,5--4 Hz generalized spike and wave discharges (GSWD) ([@bb7000]). This pattern is usually more polymorphic and irregular that the classic 3-Hz spike-wave ([@bb7000]), but could be likewise similar and elicited by hyperventilation. Given this combination of EEG features and seizure type, GLUT1DS should be considered in the differential diagnosis of childhood (CAE) or juvenile absence epilepsy (JAE), particularly if atypical features are present ([@bb3000]). Myoclonic-astatic and myoclonic absences epilepsy phenotypes have been also reported ([@bb0090], [@bb1100]). A chronic metabolic disturbance caused by lowered glucose transport is considered to be responsible for generalized epileptiform activities and epilepsy in patients with GLUT1 deficiency ([@bb0120], [@bb1200]).

This study is the first investigation of the brain networks involved in the generation of GSWD in GLUT1DS by means of EEG co-registered with fMRI (EEG-fMRI). In particular, we aimed to isolate the BOLD correlates of GSWD in GLUT1DS with respect to the ones typically observed in GGE ([@bb0025], [@bb0075], [@bb0105], [@bb0095]). This objective could be relevant for the following reasons: (a) to better understand the pathophysiology GLUT1DS; (b) to provide imaging biomarkers of the disorder that might orient the diagnosis; (c) to evaluate the mechanisms of 'generalized' SWD in a model not due to a channelopathy.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

Eighteen Italian GLUT1DS patients (mean age 19,22 years; range 6--43 years; 12 females) were enrolled from September 2012 to March 2015. The recruited subjects fulfilled the clinical criteria for diagnosis of GLUT1DS ([@bb0130]) and all but one presented pathogenic mutations in *SLC2A1* gene ([Table 1](#t0005){ref-type="table"}).

The clinical, molecular methods and genetic features of this GLUT1DS cohort have been previously described ([@bb0060], [@bb5000] Ragona et al., 2014; Veggiotti et al., 2010; [@bb0190]). Briefly, mutation analysis of all exons and intron-exon boundaries of *SLC2A1* was performed on genomic DNA by direct sequencing. Each fragment was sequenced on both strands. The effect of the newly detected *SLC2A1* mutations on protein structure or function was analyzed with the prediction programs ExPASy (<http://www.expasy.org>).

The mean age at diagnosis was 16,2 ± 11,1 years. Structural MRI scan (3T) was normal in all cases. All patients but 2 (\#6; \#18) experienced epileptic seizures (mean age of seizure onset was 34 ± 21 months). The most representative seizure\'s type was AS (10 out of 18 patients) followed by generalized tonic-clonic and myoclonic seizures. Notably, four patients had AS alone and one patient had myoclonic seizures without movement disorders. Eleven out of 18 GLUT1 subjects presented complex movement disorders, like ataxia, dystonia, chorea and paroxysmal exercise-induced dyskinesia. An intellectual impairment of variable degree was detected in 8 patients (according to the Diagnostic and Statistical Manual of Mental Disorders-DSM V). The rest of the sample displayed normal intellectual abilities, although for most of them the IQ was in the low range of normality. Seven out of the patients were on ketogenic diet either at different regimens alone (patients \#4, \#6, \#11) or in combination with antiepileptic drugs (\#2, \#8, \#10, \#18).

A group of 18 patients with GGE served as control (mean age 24,88 years; range 5--48 years; 12 females). Patients were extracted from our database of GGE patients who underwent an EEG-fMRI study between April 2007--December 2013. The patients\' inclusion criteria were the followings: 1) documented GSWD with AS during routinely video-EEG monitoring; 2) routine EEG showing normal background; 3) normal developmental milestones; 4) normal structural imaging on anatomic MRI at 3T. The GGE syndromes classification was obtained by two expert epileptologists after a careful revision of clinical and electrophysiological data of each patient (S.M., A.E.V.) according to the ILAE classification ([@bb5100]). [Table 2](#t0010){ref-type="table"} summarizes the clinical and EEG findings of GGE population.

The human ethic committee of the University of Modena and Reggio Emilia approved this study and written informed consent was obtained from all the patients and from their parents if underage.

2.2. EEG with fMRI recordings and analysis {#s0020}
------------------------------------------

Video-EEG signals have been recorded by means of a 32 channels MRI compatible EEG recording system (Micromed, Italy). Patients were asked to rest with eyes closed and keep still. All recordings were performer in the early afternoon. Sedation was never used. After the fMRI acquisitions, both GLUT1DS and GGE patients were interviewed for discomfort or any clinical, even subjective, ictal events while scanning.

fMRI data (30 axial slices, TR/TE = 3000/50 ms) have been acquired using a 3T scanner (Philips) over three 10-min sessions (200 volumes/session) with continuous simultaneous Video-EEG recording. A high-resolution T1-weighted anatomical image was obtained for anatomical reference (170 sagittal slices, TR/TE = 9.9/4.6 ms).

After offline correction of the gradient artifacts and filtering of the EEG signal ([@bb1000]), the EEG data were reviewed and pre-processed according to our previous published method ([@bb2000], [@bb0150]). Two experienced electroencephalographers reviewed the pre-processed EEG recordings independently (A.R., P.V.) in order to identify GSWD. After identification, epileptiform activities were manually marked on EEG and exported as single event or variable-length blocks depending on their duration observed by EEG.

The Matlab 7.1 and SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/>) software was used for data analysis. All functional volumes were slice time corrected, realigned to the first volume acquired, spatial normalized and smoothed with 8 × 8 × 8 mm full-width half maximum Gaussian Kernel. Movement artifacts individuated by analysis of Video-EEG recordings (blinking, lip smacking, swallowing, head movements) were considered as confounders in the model and treated as stick functions or blocks as appropriated ([@bb0150]). In addition, 24 realignment parameters \[six scan realignments parameters from image pre-processing and a Volterra expansion of these ([@bb4000])\] were included in the model as confounds.

### 2.2.1. First level analysis {#s0025}

Maps of the t-statistic were created using the timing of the GSWD as events (stick functions or blocks) within the General Liner Model (GLM) framework. In case of blocks, the duration of GSWD was specified. All regressors were convolved with the canonical hemodynamic response function (HRF) plus its temporal and dispersion derivatives ([@bb8000]).

### 2.2.2. Group level analysis {#s0030}

The effect of GSWD at the group level was tested for GLUT1DS and GGE patients separately by means of the fixed-effect or the random approach as appropriate ([@bb0070]). When using the fixed-effect model, a conjunction analysis of the BOLD increases and decreases effects for all the subjects was done with global null hypothesis, to evaluate whether the selected congruent contrasts were consistently high and jointly significant ([@bb0070]). For the random effect analysis, a full factorial design was used to test for within effects (1-way analysis of variance \[ANOVA\]) with 1 group of patients (18 GGE) and three basis functions (canonical HRF and its derivatives) as factors. Group analysis results were considered significant at the *p* \< 0.05 corrected for FWE or, if any results were revealed, a less conservative statistical inference was considered (*p* \< 0.001, uncorrected). In these cases, an additional threshold of 5-voxels extent was applied in order to discard BOLD changes occurring in scattered voxels. The fMRI t-maps were superimposed on the canonical T1-weighted images as implemented in SPM8.

Subsequently, we compared the BOLD changes obtained in the two populations in order to isolate the GSWD-related hemodynamic patterns specific of the two epileptic conditions. To this end, 10 age and sex matched GGE patients were extracted from the whole GGE sample (patient \#7, \#9, \#10, \#11, \#12, \#13, \#14, \#15, \#17, \#18). Within this subgroup, a total number of 149 GSWD were recorded (mean duration 4,59 s). A single fixed effect analysis that included both groups in one matrix (10 GLUT1DS and 10 GGE) was performed. The GSWD effect across the 10 GGE patients was obtained using fixed effect approach with conjunction analysis ([@bb0070]) similar to what previously described for GLUT1DS. Further, we explored the differences by applying an exclusive masking procedure between the conjunction contrasts each related to the specific patients\' populations. In details, to isolate the brain regions that were significantly involved in the main effect "GSWD \> baseline" in GLUT1DS population but not in the main effect "GSWD \> baseline" in GGE, the conjunction contrast "GSWD \> baseline" in GLUT1DS was exclusively masked by the mask conjunction contrast "GSWD \> baseline" in GGE. By counterpart, to isolate the brain regions exclusively activated by GSWD in GGE, the conjunction contrast "GSWD \> baseline" in GGE was exclusively masked by the conjunction contrast "GSWD \> baseline" in GLUT1DS. SPM exclusive masks were thresholded at *p* \< 0.05 uncorrected, whereas the contrasts to be masked were thresholded at *p* \< 0.001. In this way, those voxels that reached a level of significance at *p* *\<* 0*.*05 in the mask contrast were excluded from the analysis.

Finally, for the GLUT1DS patient group only, we performed additional whole brain second-level correlations analyses between the contrast (GSWD) and the main clinical measurements including: age (years); age at seizure onset (months); total IQ; glycorrhachia values (mg/dl) and the CSF/plasma glucose ratio at the time of diagnostic workup. We also explored the effect of the ketogenic diet (KD) on the GSWD-related BOLD changes. Indeed, five GLUT1DS patients (\#6, \#8, \#10, \#11, \#18) were on KD (alone or with antiepileptic treatment-AED) (KD +) at the time of the fMRI study, while the remaining were naïve (\#13) or only under AED (\#3, \#5, \#9, \#17) (KD-). In a separate analysis, we have performed a conjunction analysis, based on the fixed effect model, of the GSWD-related T contrast in the KD + subgroup and then we compared this effect with the one obtained in KD-. The differences were explored by applying an exclusive masking procedure at a threshold of *p* *\<* 0*.*05, uncorrected for multiple comparisons.

3. Results {#s0035}
==========

3.1. EEG findings during fMRI {#s0040}
-----------------------------

In GGE, EEG during fMRI shown symmetric and synchronous generalized 3--4 Hz SWD in all the patients. A total of 293 events (mean of 17 events per subject) were acquired, from a minimum of three GSWD in subject \#8 and \#12, to a maximum of 47 events in subject \#15. The duration of GSWD ranged from 1 s to 15 s, with a mean duration across subjects of 4.2 s (see [Table 2](#t0010){ref-type="table"}). The GSWD occurrence was not accompanied by clinical manifestations, even subjective, in any patients.

In GLUT1DS, EEG during fMRI revealed SWD in 10 subjects. Six patients (\#3, \#5, \#6, \#9, \#11, \#17) presented 3--4 Hz diffuse spike-and-waves discharges; four patients showed more focal discharges over the bilateral frontal leads (\#8, \#10, \#13, \#18). A total number of 152 SWD were recorded (range: 6--28). The duration of GSWD ranged from 1 s to 18 s, with a mean duration across GLUT1DS of 4,31 s (see [Table 3](#t0015){ref-type="table"}). [Fig. 1](#f0005){ref-type="fig"}, panel A shows the EEG pattern in a representative case (\#10). The GLUT1DS patients did not shown any clinical seizures, even subtle or subjective, during the EEG-fMRI. In addition, no persistent or paroxysmal movement disorders (dystonia, dyskinesia, chorea) were recorded during the experimental sessions.

For both GLUT1DS and GGE populations, the absence of clinical events (seizure and movement disorder) was verified by either the inspection of the Video recorded simultaneously during fMRI acquisitions and the post-scanning individual patient\'s interview.

3.2. GSWD related BOLD changes in GLUT1DS {#s0045}
-----------------------------------------

[Table 3](#t0015){ref-type="table"} summarizes the fMRI findings at single subject level. GSWD-related hemodynamic changes were distributed homogenously across patients, revealing the involvement of the same cortico(frontal)-subcortical(basal ganglia) network. In particular, all GLUT1DS demonstrated BOLD changes at a frontal network, encompassing premotor (prefrontal cortex, supplementary motor area-SMA, cingulate cortex) (9 patients) and motor brain regions (5 subjects). The frontal BOLD response was positive in all the cases except four patients (\#6, \#8, \#13, \#18). Subcortical positive hemodynamic changes were mainly confined at the basal ganglia (putamen) (5 patients) while only one patient (\#13) demonstrated thalamic BOLD signal increases. Finally, 7 GLUT1DS demonstrated significant BOLD responses at the posterior part of the Default Mode Network, essentially as signal increases (6 subjects). [Fig. 1](#f0005){ref-type="fig"}, panel B shows the GSWD-related fMRI map in a representative case (\#10).

At the group-level, fixed effect analysis (*p* \< 0.05 corrected for FWE) showed BOLD positive changes over the bilateral premotor cortex (global maxima-GM) (Brodmann Area-BA9), precuneus (BA7), inferior frontal gyrus (BA46) and SMA (BA6), while decreases involved the bilateral motor cortex (BA2) and the pericentral lobule (BA5) ([Fig. 2](#f0010){ref-type="fig"}A). At a less conservative threshold (*p* \< 0.001 uncorrected) a bilateral thalamic deactivation was detected. The conjunction analysis (*p* \< 0.001 uncorrected) revealed commonalities in BOLD signal increases between the ten subjects in the bilateral premotor cortex (GM) and right putamen; negative BOLD changes were detected in the thalamus, primary motor cortex, inferior frontal gyrus. The BOLD increase in the premotor cortex survived at a more conservative threshold (*p* \< 0.05 corrected for FWE) ([Fig. 2](#f0010){ref-type="fig"}B).

3.3. GSWD-related BOLD changes in GGE {#s0050}
-------------------------------------

At the group level (n. of patients = 18), random effect analysis (*p* \< 0.05 corrected for FWE) revealed BOLD signal increases in the bilateral thalami (GM) and cerebellum, while negative changes were observed in the posterior part of the Default Mode Network (DMN) encompassing the bilateral precuneus (BA7), and inferior parietal lobule (BA40) ([Supplementary Fig. 1](#f0020){ref-type="graphic"}). When the analysis was limited to 10 GGE, the conjunction approach based on the fixed-effect model revealed commonalities in BOLD signal increases in the bilateral thalami (more right) and cerebellum.

3.4. GLUT1 versus GGE {#s0055}
---------------------

GLUT1DS patients demonstrated during GSWD increased neuronal activity in the bilateral putamen, precuneus, middle cingulate cortex, right SMA and right paracentral lobule, while GGE do not ([Fig. 3](#f0015){ref-type="fig"}A). On the contrary, no GGE-exclusive GSWD-BOLD correlates were observed at the considered threshold.

3.5. Correlations between BOLD signal and clinical measures {#s0060}
-----------------------------------------------------------

Whole-brain correlation analyses using individual clinical characteristics of the GLUT1DS patients disclosed a linear positive relationship between the interictal discharges - related BOLD changes and the levels of glycorrhachia (and also CSF/plasma glucose ratio) over a bilateral cortical network including the opercular-insular cortex, the post-central cortex and superior parietal lobuli ([Fig. 3](#f0015){ref-type="fig"}B). No significant correlations were discovered with the age, age at seizure onset, and the total IQ. The conjunction analysis limited to KD + patients (*p* \< 0.001, uncorrected for FWE) demonstrated common BOLD positive responses over the bilateral precuneus, bilateral inferior parietal lobule, right precentral gyrus and a small spot in the left putamen (data not shown). No negative responses were detected. The comparison between the hemodynamic changes in GLUT1DS KD + versus KD-, did not isolated any BOLD cluster specific of GLUT1DS KD + and viceversa, at the considered threshold.

4. Discussion {#s0065}
=============

This work represents the first attempt to investigate the hemodynamic correlates of interictal epileptiform activity (IED) in a cohort of patients with GLUT1DS. To note, previous functional neuroimaging studies in these patients ([@bb0010], [@bb0120], 2007; [@bb0160]) were unable to obtain the EEG recordings at the time of imaging and the interictal/ictal state was assessed only by clinical inspection. In our study, the video-EEG recorded simultaneously during fMRI acquisitions allowed both to record the cerebral brain activity and to exclude the presence of any clinical seizure as well as paroxysmal movement disorder during the experimental sessions. Consequently, the resulted maps represent a real-time picture of brain function during IED in GLUT1DS.

The studied population is representative of the complex phenotypical spectrum of the disorder and particularly with early onset absence seizures as the main seizure type ([@bb0020], [@bb3000], [@bb7000] [@bb0155], [@bb0185]) and paroxysmal exertion-induced dystonia (PED) as most frequent movement disorder ([@bb0160]). However, epilepsy and motor signs were not homogenously distributed across patients as well as treatment and age at the time of the fMRI study. This heterogeneous presentation reflects the intrinsic and natural variability of the syndrome, as largely documented ([@bb0030], [@bb0055], [@bb0060], [@bb0180]). The clinical variability of GLUT1DS represents a difficulty to diagnose the disorder, especially for patients with mild or non-classical phenotype, who are likely to be under-diagnosed ([@bb0030], [@bb0060]). In this contest, the present work might be of importance to underlie the pathophysiological fingerprints of this metabolic encephalopathy.

As far as the fMRI analyses, the results of our work are innovative for two main aspects. Firstly, the observed BOLD findings allowed delineating a well-defined network of cortical-subcortical regions that are involved in the generation of GSWD in GLUT1DS. The results at the second level analysis showed an increase BOLD signal, and hence an increased neuronal activity, in the premotor-striatal network (bilateral premotor cortex, SMA, anterior cingulate and basal ganglia) and a simultaneous reduced metabolic demand of the motor cortex and thalamus. Notably, the analysis of single-subject GSWD-related BOLD changes was consistent with the group results as most of the patients showed significant BOLD changes within the premotor-basal ganglia circuit (see [Table 3](#t0015){ref-type="table"}). The altered metabolism of thalamus and cortico-striatal pathways found in our patients speaks to the severe abnormality of this functional system and leads us to hypothesize that it constitutes the central epileptogenic substrate in GLUT1DS.

As second main result, our findings shown that the BOLD dynamics related to GSWD in GLUT1DS are substantially different from the BOLD correlates of GSWD in typical genetic generalized epilepsies ([@bb0005], [@bb0025], [@bb0040], [@bb0075], [@bb0080], [@bb0095], [@bb0110], [@bb0170]), reinforcing the hypothesis of a specific relationship with the GLUT1DS disorder. Intriguingly, the cortical networks observed in GLUT1DS patients are very similar to the one described, by means of EEG-fMRI, in patients with 'Doose syndrome' or Myoclonic Astatic Epilepsy (MAE) ([@bb0115]). This commonality is of particular interest since MAE has been reported as one of the possible phenotypes of GLUT1DS ([@bb1100]). With respect to the BOLD findings previously reported in MAE ([@bb0115]), and more in general to GGE sub-syndromes, our GLUT1 population didn\'t show any increase in BOLD signal at thalamic level and no decreases in the Default Mode Network (DMN) at a group level. By contrast, GLUT1DS revealed bilateral activation in the putamen and different premotor and parietal areas ([Fig. 3](#f0015){ref-type="fig"}A); this pattern in not generally reported in GGE, except for single cases description (see [@bb0035] as review). The consistency of 3--4 Hz GSWD associated hemodynamic changes in GGE across studies, further support that the mechanisms subserving GSWD generation in GLUT1DS involve different neural dynamics. The irregular and slower phenotype of GSWD in GLUT1DS might partially explain these BOLD differences. Nevertheless, previous evidences failed to detect specific hemodynamic pattern linked to different GGE subgroups, independently to the morphology and length of GSWD ([@bb0140]).

The revealed hemodynamic changes in GLUT1DS are concordant with findings observed by means of positron emission tomography (PET) imaging in humans ([@bb0010], [@bb0120]--2007; [@bb0160]). Overall considered, interictal ^18^F-fluorodeoxyglucose PET demonstrated a relatively homogeneous pattern with glucose hypometabolism in the mesial temporal regions, pre-postcentral gyrus, premotor cortex, inferior parietal lobule and thalamus, and a relative increased in the basal ganglia (putamen). These PET findings demonstrated to be stereotyped regardless of disease severity, or type and duration of therapy, and persist into adulthood ([@bb0120]--2007). In other words, hypometabolism pattern may not show a progressive changes with increasing age or clinical course of seizures ([@bb0010]). This argument is concordant with our fMRI findings, as similar BOLD patterns were observed in adults and children and no relationship has been detected between age and IED-related hemodynamic changes. To note, we observed that BOLD signal related to epileptic discharges at the time of fMRI correlated with the level of CSF glucose at the time of diagnosis ([Fig. 3](#f0015){ref-type="fig"}B). This means that the lower the CSF glucose in early childhood, the lower are the BOLD signal changes IED-related, several years later at the time of the imaging study. Such linear correlation is particularly evident at the bilateral sensory-motor and parietal circuits which neuronal activity is highly dependent to the glucose supply especially in early infancy ([@bb0045]). This finding supports the observations of [@bb0010] who suggested "that brain glucose hypometabolism, present in infancy, leaves an imprint that persists even when the precipitating condition causing the hypoglycorrachia is corrected". Probably, hypoglycorrachia during a vulnerable period in early infancy can affect the maturation of the developing striatal-thalamo-cortical networks and synaptic connections, leaving a persistent alteration even when hypoglycorrhachia is corrected. As far as the correlation between the GSWD-related BOLD changes and other clinical variables, no relationship was detected with the type of treatment, particularly in relation to the presence/absence of KD (KD + versus KD-). Such inconclusive result needs to be taken with caution given the low number of patients in each subgroup. A further dedicated study on a larger cohort of GLUT1DS patients with IED during fMRI scanning and different treatments (KD and/or AED) needs to be performed to test the specific effect of KD on the brain networks function in GLUT1DS.

Our fMRI results demonstrated that the disrupted metabolism of the premotor-basal ganglia circuit is responsible for the generation and maintenance of interictal GSWD. Since we did not record any clinical seizure as well as involuntary movements during the experimental sessions, we could not directly link the detected hemodynamic changes with these clinical phenomena. Previous attempts to segregate the PET patterns based on the GLUT1DS clinical phenotype shown that a prominent hypometabolism in the thalamus and mesial temporal cortex linked to the presence of epilepsy ([@bb0010]) while PED frequency score was positively correlated to the metabolic activity of basal ganglia (putamen), and negatively with the premotor cortex (anterior cingulate and superior frontal cortex) ([@bb0160]). Intriguingly, ictal SPECT during a PED episode shown hyper-perfusion over the motor cortex and putamen ([@bb0160]). Based on these observations, a dysfunction of the cortico-striatal pathways has been postulated to play a role in the pathophysiology of PED ([@bb0160]). Our fMRI maps appear to support this hypothesis as most of our patients shown PED as the main motor disorder. It is likely that an altered excitability of striatal-thalamo-(frontal)cortical pathway, which is the consequence of a defect in glucose transport across the blood-brain barrier, subserves the generation of both epileptic activity and PED. Given the lack of movement disorders during fMRI, this conclusion remains speculative and warrants further investigations to be confirmed.

The pathogenic role of low CSF glucose to determine GLUT1DS phenotype, including seizures, has been objected of intense speculations ([@bb0015], [@bb0020]). The primary mechanism in GLUT1 deficiency seems represented by a reduced substrate delivery rather than altered membrane excitability as observed in channelopathies ([@bb0015], [@bb0020]). Furthermore, most likely, there is reduced availability of interstitial medium glucose to both astrocytes and neurons, the former of which rely on GLUT1 for their glucose uptake, unlike neurons that utilize the transporter GLUT3 ([@bb1300]). Thus, the astroglial glucose uptake is severely compromised being restricted by its failure at both the blood-brain barrier and the cellular membrane. This astroglial failure could result in a decrease in the amount of lactate produced for subsequent delivery to the neuron ([@bb0135]) resulting in downstream neuronal dysfunction. An early effect of this pathogenic mechanism on the structures that first start to mature, like thalamus, might constitute the basis of the epileptiform abnormalities in neuroglycopenia ([@bb6000]). An altered thalamic function, indeed, might affect the cortico-thalamic and thalamo-cortical oscillatory networks, leading to synchronized spike-and-wave discharges ([@bb0085], [@bb0100]). In line with this proposed mechanism, our findings indicate an opposite BOLD response in the thalamus (negative change) and cortico-striatal circuit (positive change). We might hypothesize that the reduced metabolic activity of the thalamic regions leads to a change in the activity of the connected cortico-striatal areas, resulting in their reduced inhibition and hence hyper-excitation. Certainly, given the limited sample of patients investigated, further studies are needed to replicate our findings on a larger cohort of GLUT1DS subjects.

4.1. Study limitations {#s0070}
----------------------

The major limitation of this study is related to the number of the investigated subjects, which is justified by the rarity of this genetic disorder. This limitation might lead to caution in generalizing the results outside of the group of subjects analyzed. The fixed effect approach applied within the GLUT1DS cohort and between the GLUT1DS and GGE, allows to make a comment about the specific subjects studied (only those) but it cannot be used to obtain an inference at the population level. However, by using a conjunction approach, based on the fixed-effect model, we were able to infer that at least some proportion of the population from which the patients came show this effect ([@bb0070]), i.e. to extend our speculations to the general GLUT1DS population.

4.2. Conclusions {#s0075}
----------------

In conclusion, our study provides new findings on the epileptic networks subserving epilepsy in GLUT1 deficiency syndrome. Several question, however, are unanswered and should be addressed by future studies investigating both microstructural abnormalities in GLUT1 patients with milder form of the disease, as well as the integrity or alteration of resting-state networks subserving motor and cognitive functions.

The following is the supplementary data related to this article.Supplementary Fig. 1Results of GSWD-related second level analysis in GGE population. GSWD-related random effect analysis results (*p* \< 0.05 corrected for FWE) are shown on the canonical T1 image, axial, coronal and sagittal view. Positive BOLD changes are displayed in red color, negative in blue. See text for details. L = Left; R = Right.Supplementary Fig. 1
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![EEG-fMRI results in a representative GLUT1 patient.\
*Panel A*: Representative EEG recorded during fMRI acquisition in patients \#10. The EEG is displayed in bipolar montage after gradient and pulse artifact correction. Note the burst of 1.5--2 Hz SWD over the bilateral frontal fields. *Panel B*: fMRI results (*p* \< 0.05 corrected for FWE) overlaid to the canonical T1 image, axial, coronal and sagittal slice. Significant BOLD signal increases were detected at the bilateral middle frontal gyrus (global maxima) (BA6), supplementary Motor Area (SMA) (BA6), putamen, post-central cortex (BA40), inferior frontal gyrus (BA9), left anterior cingulate cortex (BA32), left precuneus (BA19). No BOLD decreases were detected. R = Right; L = Left; BA: Brodmann Area.](gr1){#f0005}

![Results of SWD-related second level analysis in GLUT1DS.\
*Panel A*: FFX {T} BOLD signal changes across the 10 GLUT1DS with recorded SWD. Positive (in red) and negative (in blue) BOLD responses are displayed onto the T1-canonical image, axial slices (*p* \< 0.05 corrected for FWE). See text for a description of positive and negative BOLD correlations. *Panel B*: Conjunction analysis results (*p* \< 0.001, uncorrected) shown common areas of positive and negative BOLD correlation with the SWD across the 10 GLUT1DS subjects. L = Left; R = Right.](gr2){#f0010}

![Specific BOLD response to GSWD in GLUT1DS and correlation with clinical variables.\
*Panel A*: the main effect conjunction contrast "GSWD \> baseline" in GLUT1DS was exclusively masked by the mask conjunction contrast "GSWD \> baseline" in GGE, at a threshold of *p* \< 0.05, uncorrected for multiple comparison. GSWD-related BOLD signal increases specific to GLUT1DS were detected at the bilateral putamen, precuneus (BA31), middle cingulate cortex (BA32), SMA (BA6) and right paracentral lobule (BA5). Clusters of activation are overlaid on the canonical T1-weighted structural scan.\
*Panel B:* A linear correlation between BOLD changes and levels of glycorrhachia is evident in GLUT1DS. The results are displayed onto canonical render images (*p* \< 0.001, uncorrected). The graph demonstrated the positive correlation between the two variables (right image). L = Left; R = Right, BA: Brodmann Area.](gr3){#f0015}

###### 

Clinical feature and genetic of GLUT1 patients.

Table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt ID   Age(yrs)/sex   Age at diagnosis (yrs)   Glycorrhachia (mg/dl)   CSF/plasma glucose ratio   Protein mutation   Seizure type   Seizure onset (mo)   Sporadic/Familiar   Motor Signs    IQ    Treatment at fMRI
  ------- -------------- ------------------------ ----------------------- -------------------------- ------------------ -------------- -------------------- ------------------- -------------- ----- -------------------
  1       12/M           6                        35                      0.54                       c1457delG_1\       GTC, AS        11                   S                   PED, Dy        75    VPA
                                                                                                     delG SPL                                                                                        

  2       11/F           10                       33                      0.34                       R126C              Myo, AS        30                   S                   PED, Dy        44    LEV, LTG, 3:1 KD

  3       14/M           11                       44                      0.51                       R223W              FS             11                   S                   PED, Cho       75    OXC

  4       9/F            5                        31                      0.39                       R153C              GTC, AS        12                   F                   A              104   1.8:1 KD

  5       12/M           10                       40                      0.47                       R458W              FS             40                   F                   PED, Cho       85    VPA

  6       10/F           10                       33                      0.38                       V165I              /              /                    F                   PED, Dy, Cho   66    3:1 KD

  7       7/F            7                        32                      0.35                       N34S               AS             24                   F                   /              76    ETS

  8       12/F           9                        34                      0,38                       R400C              AS, Myo        36                   S                   PED, Dy        50    LTG, 3:1 KD

  9       6/F            5                        40                      0,41                       not found          Myo, GTC       39                   S                   /              112   VPA, LTG, CLB

  10      27/F           20                       31                      0.38                       R126C              AS, FS Myo     8                    S                   PED, A         60    LEV, 3:1 KD

  11      18/F           14                       40                      0.44                       P36R               AS             18                   S                   /              53    2,5:1 KD

  12      28/M           17                       46                      0.54                       R458W              FS             60                   S                   PED, Dy        57    ETS

  13      43/F           43                       N/A                     N/A                        R458W              AS             72                   F                   /              78    --

  14      40/F           29                       41                      0.44                       V165I              AS, GTC        12                   F                   PED            55    VPA

  15      24/F           24                       N/A                     N/A                        V165I              AS             72                   F                   /              76    --

  16      19/F           19                       38                      0,5                        1166delV           AS             48                   S                   PED. Dy        80    LTG

  17      39/M           39                       42                      0.43                       N34S               AS             48                   F                   PED, Dy        75    CBZ

  18      15/M           15                       44                      0,44                       R400H              /              /                    S                   PED, Dy        56    VPA, 3:1 KD
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend [Table 1](#t0005){ref-type="table"}: M: Male; F: Female; A; Ataxia; AS: absences seizures; Cho: chorea; Dy: Dystonia; GTC: generalized tonic clonic seizures; FS: focal seizures; Myo: Myoclonic Seizures; N/A: not available; PED: paroxysmal exercise-induced dyskinesia. LEV: Levetiracetam; LTG: Lamotrigine; VPA: Valproate; ETS: Ethosuximide; CBZ: Carbamazepine; CLB: Clobazam; KD: ketogenic diet. S: sporadic; F: familiar.

Missense mutations were observed in the majority; case \#1 and n \#16 presented deletions. Amino acid mutations are represented by (capital) native amino acid (in one-letter code), amino acid number, and mutant amino acid. Nucleotide deletions are indicated by nucleotide number, del for deletion, nucleotide, or by native nucleotide, number, and mutant nucleotide.

###### 

GGE population: clinical features and details of the EEG data during fMRI.

Table 2

  Clinical Data   GSWD during fMRI                                                                                               
  --------------- ------------------ ------------------- ------------ ----------- --------------------- ------------------------ ------------------------
  Pts ID          Age (years)/sex    Epilepsy syndrome   AEDs         N° events   Mean duration (sec)   Minimum Duration (sec)   Maximum Duration (sec)
  1               24/F               JAE                 LEV          45          3,24                  1,5                      5,4
  2               33/F               JAE                 VPA          15          3,61                  0,8                      6,8
  3               47/M               JAE                 VPA          21          3,71                  2                        5
  4               48/F               CAE                 VPA          14          4,03                  1,2                      6,1
  5               26/M               Adult onset IGE     PB/TPM/ZNZ   12          4,99                  2                        7
  6               37/F               JAE                 LEV          19          3,91                  1,6                      8,1
  7               14/F               JAE                 VPA          16          3,18                  1,1                      6,9
  8               23/F               Adult onset IGE     LEV          3           3,07                  0,9                      5
  9               5/F                CAE                 Naïve        5           5,20                  2,2                      7
  10              20/F               JAE                 Naïve        9           3,14                  1,1                      5,2
  11              12/M               CAE                 Naïve        5           7,29                  2,2                      10
  12              9/F                CAE                 Naïve        3           7,63                  1,1                      15
  13              11/M               JAE                 VPA          9           5,19                  3,1                      7,6
  14              10/F               CAE                 Naïve        6           5,07                  2,2                      6,9
  15              41/F               Adult onset IGE     LEV          47          2,13                  1                        5
  16              35/F               JAE                 VPA          15          2,45                  2,2                      3,6
  17              15/M               JME                 LEV          8           3,40                  2,1                      4,4
  18              38/M               JAE                 VPA          41          3,74                  1.7                      6,6

Legend [Table 2](#t0010){ref-type="table"}: M: Male; F: Female; JAE: juvenile absence epilepsy; CAE: childhood absence epilepsy; GGE: genetic generalized epilepsy; JME: juvenile myoclonic epilepsy; AEDs: antiepileptic drugs; VPA: valproate; LEV: levetiracetam; PB: phenobarbital; TPM: topiramate; ZNZ: zonisamide; GSWD: generalized spike-wave discharge.

###### 

EEG and fMRI results at single-subject level.

Table 3

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PT ID   ED               Bold changes                                                                                                                                                                                        
  ------- ---------------- -------------- ------ ------- --------------------- --------------------- ------------------------ ------------------------ ----------------------- ----------------------- ----------------------- ---------------------------
  Pt3     B F SWD          12/11,89       2,68   18,1    B (\> R) (3.51) (i)   B (\> L) (4.94) (i)   B (\> R) (5.07) (i)      L (4.50) (i)             --                      --                      L (4.90) (i)            --

  Pt5     Diffuse SWD      6/2,1          1      3.24    --                    B(\> R) (4.82) (i)    R (4.88) (i)             --                       --                      --                      --                      --

  Pt6     Diffuse SWD      12/2,17        0,36   4,53    B (\> L) (2.58) (i)   --                                             L (3.46) (d)\*           B (\> L) (2.89) (d)\*   B (\> L) (3.82) (d)\*   --                      B cerebellum (2.99) (d)\*

  Pt8     B F SWD (\> L)   11/2,14        0      4.01    --                    --                                             R (d)\*                  --                      --                      --                      --

  Pt9     Diffuse SWD      15/3,2         0      15.24   L (2.72) (i)\*        --                    R (4.35) (i)             L (3.02) (i)\*           --                      B (\> R) (3.75) (i)\*   B (\> R) (4.30) (i)\*   B cerebellum (4.32) (i)

  Pt10    B F SWD          18/4,28        1      17,84   B (\> L) (4.86) (i)   B(\> L) (3.99) (i)    B (\> R) (\> 7.59) (i)   B (\> L) (\> 7.59) (i)   L (\> 7.59) (i)         B (\> L) (6.35) (i)     L (5.07) (i)            --

  Pt11    Diffuse SWD      15/1,34        0      2,05    --                    B (4.92) (i)          --                       B (4.94) (i)             --                      --                      B (6.15) (i)            --

  Pt13    B F SWD          28/3,6         0      15,8    L (3.82) (i)\*        B (\> R) (5.67) (d)                            B (\> R) (6.41) (d)                              B (\> R) (7.81) (d)     B (\> L) (7.81) (d)     B thalamus (4.40) (i)\*\
                                                                                                                                                                                                                               B cerebellum (4.12) (i)\*

  Pt17    Diffuse SWD      10/3           1      4,5     --                    --                                             --                       --                      B (\> R) (3.32) (i)\*   B (\> R) (3.17) (i)\*   L TP junction (i)

  Pt18    B F SWD          25/3,5         1      8,4     --                    --                    B (5.39) (d)             --                       --                      --                      R (3.77) (i)\*          --
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend [Table 3](#t0015){ref-type="table"}: FMRI results are displayed using a threshold set at *p* \< 0.05 corrected for FWE and *p* \< 0.001 uncorrected if no BOLD changes were detected at the more conservative statistical inference (the results obtained using a *p* \< 0.001 uncorrected are indicated by the asterisk \[\*\]). The numbers in brackets indicate the maximal t-values. ED: epileptic discharges; SW: Slow Waves; SWD: spike-wave discharges; L: Left; R: Right; B: Bilateral; F: Frontal; TP: Temporo-Parietal. (i) increase BOLD signal; (d) decrease BOLD signal; L: Left; R: Right; B: Bilateral; SMA: Supplementary Motor Area; \*\*DMNp: Default-mode Mode Network which includes: posterior part of DMN (precuneus/posterior cingulate, bilateral inferior parietal lobuli).

[^1]: Equally contribution.
